Dermata Therapeutics shares surge 25.54% intraday after closing $4.1M private placement to fund OTC acne kit launch.

Dermata Therapeutics (DRMA) surged 25.54% intraday following the announcement of a $4.1 million private placement with up to $8.3 million in additional proceeds from warrants. The company issued 2.02 million shares and warrants at $2.04 per share, with insider participation and H.C. Wainwright as placement agent. Funds will support its OTC acne kit launch in mid-2026, consumer research, and strategic acquisitions. The transaction, including warrant repricing and revised terms for prior warrants, signals capital-raising success and operational focus on dermatologic product development. The intraday rally aligns with investor optimism over near-term growth initiatives and product commercialization.